Dosing & Uses
IgA Nephropathy
Pending FDA approval for IgA nephropathy (IgAN); also called Berger disease
Next:
Pharmacology
Mechanism of Action
Dual endothelin angiotensin receptor antagonist (DEARA)
Selectively blocks endothelin 1A and angiotensin II type 1 receptors
Blocking these receptors reduces proteinuria, protects podocytes, and prevents glomerulosclerosis and mesangial cell proliferation
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
